

State of Kansas
Board of Pharmacy
Notice of Hearing on Proposed Administrative Regulations

A public hearing will be conducted on Thursday, April 21, 2016 at 8:30 a.m. in room 2040 of the University of Kansas School of Pharmacy, 2010 Becker Drive, Lawrence, to review and consider the adoption of proposed permanent regulation K.A.R. 68-7-22 for the administration of the Kansas Pharmacy Practice Act, K.S.A. 65-1625 *et seq.*

This 60-day notice of the public hearing shall constitute a public comment period for submitting written public comments on the proposed regulations.

All interested parties may submit written comments prior to the public hearing as follows: by e-mail at pharmacy.intern@pharmacy.ks.gov or by mail to Alexandra Blasi, Executive Secretary, 800 S.W. Jackson, Suite 1414, Topeka, Kansas 66612-1244. The public shall be given a reasonable opportunity to present their views orally on this regulation during the hearing. In order to give all parties an opportunity to present their views, it may be necessary to request that each participant limit any oral presentation to five minutes. All public comments submitted during this period will be made part of the regulation's written record.

Any individual with a disability may request accommodation in order to participate in the public hearing and may request the regulations and economic impact statements in an accessible format. Requests for accommodation should be made at least ten working days in advance of the hearing to Alexandra Blasi, Executive Secretary, 800 S.W. Jackson, Suite 1414, Topeka, Kansas 66612-1244 or by phone at (785) 296-4056. Handicapped parking is available on the west side of the School of Pharmacy building and throughout the west campus area. Curbs at all entrances are accessible to individuals with disabilities.

Copies of the proposed regulation and economic impact statement may be accessed at <http://www.pharmacy.ks.gov/>.

K.A.R. 68-7-22. Collaborative Practice. This regulation provides definitions and standards for collaborative drug therapy management (CDTM) between pharmacists and physicians.

II. Federal Requirements. Though the Board makes every attempt to align Kansas rules and regulations with federal standards and practices, there are no federal requirements implicated by this regulation.

III. Anticipated Economic Impact on the Board. The Board anticipates that any economic impact will be related to general licensing record updates and document processing and storage. The regulation requires pharmacists update the Board with any new or updated collaborative practice agreements within five business days and report the status of any agreement biennially with their license renewal. Costs to the Board might appear in the form of staff time and are negligible in the scheme of current licensing staff functions.

IV. Anticipated Financial Impact Upon Other Governmental Agencies or Units. The Board does not anticipate that this regulation will have any financial impact upon other governmental agencies.

V. Anticipated Financial Impact Upon Small Employers and Private Citizens and Businesses. Pharmacists, physicians, and their respective private businesses engaged in CDTM may experience an economic impact. Additional time to coordinate the agreement as well as the CDTM practice may take additional time or resources, but the amount of any monetary impact is unknown. No other impact on private citizens or businesses is anticipated.

VI. Anticipated Economic Impact Upon Other Entities or Persons. There would be no negative impact on other entities or persons. There would be a positive impact on patient safety and welfare.

VII. Less costly or intrusive Methods that Were Considered, but Rejected, and the Reason for Rejection. The Board is not aware of any less costly or less intrusive methods to achieve the stated purpose and thus none were considered.

Alexandra Blasi
Executive Secretary